Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro sold 3,722 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $12.00, for a total value of $44,664.00. Following the completion of the sale, the director now directly owns 9,557 shares in the company, valued at approximately $114,684. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 1.72% during mid-day trading on Wednesday, hitting $11.41. 60,452 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock’s 50-day moving average is $11.30 and its 200-day moving average is $12.84. The company’s market cap is $587.4 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals’s revenue was up 151.1% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on MNTA shares. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.20.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Receive News & Ratings for Momenta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.